Endocrine Abstracts

Contents

• Obesity Update
• • Speaker Abstracts
  • A year in review: what are the highlights?
  • • Is obesity pharmacotherapy finally coming of age?

      ea0061ou1
    • Update on fatty liver: assessment and treatment

      ea0061ou2
    • Novel endoscopic techniques for the treatment of obesity

      ea0061ou3
  • Plenary 1: Can it be healthy to be overweight? Is so when?
  • • Can it be healthy to be overweight? If so when?

      ea0061ou4
  • Debate: Will metabolic surgery replace pharmacotherapy for the treatment of t2 diabetes?
  • • Very low calorie diets for the treatment of Type 2 diabetes and obesity are a waste of time -DEBATE

      ea0061ou5
  • Symposium: The role of weight loss in managing type II diabetes
  • • Intensive dietary lifestyle interventions in type 2 diabetes

      ea0061ou6
    • Weight lowering treatments in type 2 diabetes

      ea0061ou7
    • Metabolic surgery as a treatment for type 2 diabetes

      ea0061ou8
  • Plenary 2: CVOT's in Obesity - Where are we coming from, where are we going
  • • CVOT's in Obesity - Where are we coming from, where are we going?

      ea0061ou9
• Oral Communications
• • Case Discussions: complex clinical cases 1.0
  • • Lifestyle intervention enhances weight loss and metabolic control in GLP-1RA-initiating subjects with T2DM

      ea0061cd1.1
    • Diabetes Intervention Accentuating Diet and Enhancing Metabolism (DIADEM-I): a randomised controlled trial to examine the impact of an intensive lifestyle intervention consisting of a low-energy diet and physical activity on body weight and metabolism in early type 2 diabetes mellitus: preliminary findings

      ea0061cd1.2
    • Weight outcomes, by baseline BMI category, in patients referred to a commercial weight management programme

      ea0061cd1.3
    • Frequency of Type 2 Diabetes Mellitus in persons with different types of obesity, data of prospective observation

      ea0061cd1.4
  • Case Discussions: complex clinical cases 2.0
  • • Factors related to Non-Alcoholic Fatty Liver Disease (NAFLD) measures in obese subjects with early Type 2 Diabetes mellitus

      ea0061cd2.1
    • Simultaneous islet cell and kidney transplant in a patient with Type 1 Diabetes and End-Stage Renal Failure after Roux-en-Y gastric bypass

      ea0061cd2.2
    • Exploring the roles of Annexin A1 in adipocytes using an in vitro model of obesity

      ea0061cd2.3
• Poster Presentations
• • (1)
  • • GLP-1 agonist use in the management of obesity in Type 2 Diabetes: an Irish tertiary hospital experience

      ea0061p001
    • Metabolic changes post Roux-En-Y Gastric Bypass: one year prospective study

      ea0061p002
    • The benefits of non-surgical weight management on weight and glycaemic control in people with complex diabetes: a primary care service evaluation of clinical outcomes at 12 months

      ea0061p003
    • Evidence of aberrant inflammation in patients with Lipodystrophy

      ea0061p004
    • Metabolic health and different body composition phenotypes in a Maltese cohort

      ea0061p005
    • Recognition of the healthcare professional role pharmacy is playing in the management of weight and Type 2 Diabetes

      ea0061p006
    • 25-hydoxy vitamin D and cardio-metabolic risk factors in obesity with early Type 2 Diabetes mellitus

      ea0061p007
    • Evaluating the effect of seaweed and alginate enriched cheeses on wellbeing outcomes in a nutritional intervention study (pilot study)

      ea0061p008
    • The effect of high protein meal on Glycaemic Indices and Gut Hormones Profiles in patients with Post-Bariatric Hypoglycaemia

      ea0061p009